We have a proven track record with immunology expertise in cancer and inflammation.
Developing novel drugs targeting a class of immune cells called myeloid cells to directly treat cancer as well as to enhance the benefits of current Immuno Oncology drugs such as checkpoint inhibitors in currently untreatable cancers.
Immuno Oncology (IO) is a new area of cancer research which has been successful in treating previously untreatable cancers. IO targets the immune system rather than the cancer directly which potentially allows a single IO drug to be used to treat multiple cancer types with mostly manageable side effects. METX
Our latest company news and scientific findings.
ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to provide an overview and update on our current research and development programs.
ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to provide an overview and update on our current research and development programs.
VANCOUVER, BC, January 14, 2025 — ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that its first therapeutic mRNA candidate from its strategic collaboration with
